

GF/B43/EDP18 Decision on the Secretariat’s Recommendation on Funding from the 2020-2022 Allocation

Approved on 6 November 2020.

The Board:

- 1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER18 (“Table 1”);**
- 2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;**
- 3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and**
- 4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.**

This decision does not have material budgetary implications for operating expenses.

Table 1: Secretariat’s Recommendation on Funding from the 2020-2022 Allocation

N	Applicant	Disease Component	Grant Name ¹	Grant End Date	Currency	Total Program Budget ²	Catalytic Funds in Grant	Domestic Commitment ³	Unfunded Quality Demand
1	Afghanistan	HIV/AIDS	AFG-H-UNDP	31/12/2023	US\$	9,522,739	-	1,573,800	3,419,698
2	Bangladesh	Malaria	BGD-M-BRAC	31/12/2023	US\$	12,951,846	-	10,480,000	9,350,322

¹ The Grant names are subject to change based on the ISO code.

² The Program budget for the Grant may be higher than the Program budget being recommended to the Board for approval where Covid-19 Response Mechanism funding has been integrated into the Grant.

³ Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies.

3			BGD-M-NMCP	31/12/2023	US\$	11,148,154	-		
4		TB	BGD-T-BRAC	31/12/2023	US\$	53,452,198	6,331,750	168,140,000	46,714,112
5			BGD-T-NTP	31/12/2023	US\$	68,314,825	3,668,250		
6	Burkina Faso	Malaria	BFA-M-PADS	31/12/2023	EUR	151,025,513	1,813,300	68,806,900	55,707,355
7	Eswatini	Malaria	SWZ-M-NERCHA	31/12/2023	US\$	2,635,791	-	2,324,450	310,773
8	Honduras	Malaria	HND-M-CHF	31/12/2023	US\$	4,032,428	-	7,440,590	611,962
9	Lao (People's Democratic Republic)	HIV/TB	LAO-C-MOH	31/12/2023	US\$	15,507,232	-	HIV: 4,202,411; TB: 4,119,182	7,675,804
10	Multicountry Americas ORAS-CONHU	TB	QRA-T-ORAS	31/10/2023	US\$	4,000,000	4,000,000	-	-
N	Applicant	Disease Component	Grant Name⁴	Grant End Date	Currency	Total Program Budget⁵	Catalytic Funds in Grant	Domestic Commitment⁶	Unfunded Quality Demand
11	Tajikistan	HIV/TB	TJK-C-UNDP	31/12/2023	US\$	25,044,957	-	HIV: 11,808,833; TB: 20,629,106	12,124,067
12	Thailand	HIV/TB	THA-C-DDC	31/12/2023	US\$	27,203,055	-	HIV: 806,684,381; TB: 133,318,240	14,804,113
13			THA-C-RTF	31/12/2023	US\$	33,445,414	-		
14	Uganda	Malaria	UGA-M-MoFPED	31/12/2023	US\$	230,825,564	3,000,000	Malaria: 3,904,950; RSSH: 190,004,165	24,074,455
15			UGA-M-TASO	31/12/2023	US\$	32,199,386			

⁴ The Grant names are subject to change based on the ISO code.

⁵ The Program budget for the Grant may be higher than the Program budget being recommended to the Board for approval where Covid-19 Response Mechanism funding has been integrated into the Grant.

⁶ Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies.

